This is a StreetInsider.com Premium Only Page

(TVTX) – StreetInsider.com Reports

Apr 25, 2024 06:40 AM Travere Therapeutics (TVTX) PT Raised to $19 at H.C. Wainwright

Apr 24, 2024 07:05 AM Travere Therapeutics (TVTX) and CSL Vifor Announce EU Approval of FILSPARI

Mar 27, 2024 06:19 AM Guggenheim Downgrades Travere Therapeutics (TVTX) to Neutral

Feb 26, 2024 06:37 AM Travere Therapeutics (TVTX) PT Lowered to $17 at H.C. Wainwright

Feb 23, 2024 07:06 AM Travere Therapeutics (TVTX) and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

Feb 23, 2024 05:43 AM Travere Therapeutics (TVTX) and CSL Vifor Report Positive CHMP Opinion for sparsentan

Feb 16, 2024 07:18 AM Travere Therapeutics (TVTX) PT Raised to $9 at Wells Fargo

Feb 15, 2024 04:08 PM Travere Therapeutics (TVTX) Tops Q4 EPS by 212c

Jan 29, 2024 07:04 AM Travere Therapeutics (TVTX) PT Raised to $13 at Wedbush

Jan 25, 2024 08:17 AM Travere Therapeutics (TVTX) PT Raised to $15 at TD Cowen

Jan 18, 2024 07:34 AM Travere Therapeutics (TVTX) PT Raised to $11 at Piper Sandler

Dec 18, 2023 07:23 AM Travere Therapeutics (TVTX) PT Raised to $10 at Stifel

Dec 18, 2023 06:37 AM Travere Therapeutics (TVTX) PT Raised to $20 at H.C. Wainwright

Dec 14, 2023 07:31 AM Travere Therapeutics (TVTX) Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase

Dec 5, 2023 09:18 AM Evercore ISI on Travere Therapeutics (TVTX): 'We think the stock remains undervalued'

Dec 5, 2023 06:55 AM Citi Upgrades Travere Therapeutics (TVTX) to Buy

Dec 4, 2023 04:06 PM Travere Therapeutics (TVTX) Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS

Nov 20, 2023 05:09 AM Citi Starts Travere Therapeutics (TVTX) at Neutral

Nov 8, 2023 06:23 AM Travere Therapeutics (TVTX) PT Lowered to $11 at Evercore ISI

Nov 7, 2023 04:23 PM Travere Therapeutics (TVTX) Tops Q3 EPS by 333c

Nov 3, 2023 10:48 AM Travere Therapeutics (TVTX) Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM

Oct 25, 2023 06:41 AM Travere Therapeutics (TVTX) PT Lowered to $10 at Piper Sandler

Oct 3, 2023 07:23 AM Travere Therapeutics (TVTX) PT Lowered to $15 at Canaccord Genuity

Sep 25, 2023 06:34 AM Travere Therapeutics (TVTX) PT Lowered to $18 at H.C. Wainwright

Sep 22, 2023 04:46 AM Wells Fargo Downgrades Travere Therapeutics (TVTX) to Equal Weight

Sep 22, 2023 03:30 AM Travere Therapeutics (TVTX) PT Lowered to $12 at Barclays

Sep 21, 2023 03:35 PM Travere Therapeutics (TVTX) PT Lowered to $14 at Evercore ISI

Sep 21, 2023 01:46 PM Travere Therapeutics (TVTX) PT Lowered to $8 at Stifel on "limited Sparsentan's competitive positioning"

Sep 21, 2023 10:40 AM William Blair Downgrades Travere Therapeutics (TVTX) to Market Perform, 'we are uncertain in the market opportunity for Filspari in IgAN'

Sep 21, 2023 09:21 AM Travere Therapeutics (TVTX) Reports Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI

Sep 21, 2023 07:40 AM Travere Therapeutics (TVTX) Declines After Mixed Data from Phase 3 PROTECT Study of FILSPARI

Sep 21, 2023 07:30 AM Travere Therapeutics (TVTX) Reports Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI Demonstrating Long-Term Kidney Function Preservation

Sep 6, 2023 05:30 AM Evercore ISI Resumes Travere Therapeutics (TVTX) at Outperform, 'sales of sparsentan in IgAN will begin to accelerate as we head into year end'

Aug 8, 2023 06:41 AM Travere Therapeutics (TVTX) PT Lowered to $32 at H.C. Wainwright

Aug 4, 2023 01:29 PM Travere Therapeutics (TVTX) PT Raised to $25 at Guggenheim

Aug 4, 2023 09:46 AM Travere Therapeutics (TVTX) PT Lowered to $25 at TD Cowen

Aug 4, 2023 07:00 AM Travere Therapeutics (TVTX) PT Raised to $17 at Stifel

Aug 3, 2023 04:13 PM Travere Therapeutics (TVTX) Misses Q2 EPS by 6c, beats revenue

Jul 21, 2023 04:22 AM JPMorgan Starts Travere Therapeutics (TVTX) at Overweight

Jul 18, 2023 08:10 AM Travere Therapeutics (TVTX) PT Lowered to $35 at Canaccord Genuity

Jul 17, 2023 09:14 AM Travere Therapeutics (TVTX) PT Raised to $41 at BofA Securities

Jul 17, 2023 08:00 AM Travere Therapeutics (TVTX) to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum (MIRM)

Jun 7, 2023 06:31 AM Piper Sandler Assumes Travere Therapeutics (TVTX) at Neutral

Jun 1, 2023 11:06 AM Travere Therapeutics (TVTX) PT Raised to $35 at H.C. Wainwright

May 31, 2023 11:56 AM Travere Therapeutics (TVTX) PT Raised to $30 at Evercore ISI

May 31, 2023 07:04 AM Travere Therapeutics (TVTX) Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria

May 22, 2023 05:51 AM TD Cowen Starts Travere Therapeutics (TVTX) at Outperform

May 9, 2023 08:09 AM Travere Therapeutics (TVTX) PT Lowered to $37 at Canaccord Genuity

May 5, 2023 08:26 AM Travere Therapeutics (TVTX) PT Lowered to $16 at Stifel

May 4, 2023 05:02 PM Travere Therapeutics (TVTX) Tops Q1 EPS by 115c